Allscripts Healthcare Stock
Allscripts Healthcare Stock
Allscripts Healthcare dominated the market today, gaining €0.000 (21.430%).
With 0 Sell predictions and 2 Buy predictions the community sentiment towards the Allscripts Healthcare stock is not clear.
As a result the target price of 11 € shows a positive potential of 29.41% compared to the current price of 8.5 € for Allscripts Healthcare.
Pros and Cons of Allscripts Healthcare in the next few years
Pros
?
B****
?
W********* I********* f** t** n*** y****
?
S********** s********
Cons
?
G***** c******* t* c**********
?
M***** P*******
?
C******** o* t** e**********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Allscripts Healthcare vs. its peers
Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
---|---|---|---|---|---|---|---|
Allscripts Healthcare | 21.430% | 0.000% | 18.056% | -17.476% | -8.108% | -41.781% | -5.081% |
MicroVision Inc | -5.640% | -9.939% | -14.533% | -77.913% | -64.047% | -94.742% | 25.121% |
Fonar Corp. New | 1.450% | -4.167% | -3.497% | -12.102% | -22.034% | -2.817% | -26.697% |
Fluidigm Corp. | -1.530% | -7.547% | -14.035% | 1.031% | -4.854% | -61.318% | - |
Comments
Veradigm Inc. (NASDAQ: MDRX) had its price target lowered by analysts at TD Cowen from $26.00 to $15.00. They now have a "buy" rating on the stock.
Show more
Ratings data for MDRX provided by MarketBeat
Veradigm Inc. (NASDAQ: MDRX) had its price target lowered by analysts at Royal Bank of Canada from $22.00 to $11.00. They now have an "outperform" rating on the stock.
Show more
Ratings data for MDRX provided by MarketBeat